comprehensive -WSS

comprehensive

author：focus 2025-10-02 10:45:37 - browse：883

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： How doctors and nurses shape Google's AI

WSS

Investment in vaccine development is lagging, report finds

Peter Marks talks Operation Warp Speed for Rare Diseases

Pancreatic cancer early detection could be helped by AI

Researchers CRISPR chickens in bid to protect them from bird flu

Better Therapeutics data on benefit with GLP

How generative AI ratchets up security threats for health systems

leisure time

comprehensive

knowledge

Heart attack and stroke risk calculators need revising

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

As demand for Covid shots wanes, Moderna seeks its next success

Vertex non

State Dept. review finds Biden bears some blame for Afghanistan failures

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

How to save PrEP access — and even expand it

Medicare drug price negotiation legal challenge met with skepticism

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

leisure time

Massive project maps cells in human brain in unprecedented detail

How generative AI ratchets up security threats for health systems

Boston competes with Raleigh

European regulators consider appeal over Amylyx ALS drug

Medicare to cover more brain scans related to Alzheimer’s drugs

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Wikipedia

leisure time

explore

Wikipedia